HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA GMP Warnings To OTC Firms In China, South Korea

Executive Summary

Cosmo Bio's response to remote records request shows the South Korea company was marketing an unapproved OTC acne treatment without adequate release or stability testing. In China, Hubei Kangzheng was manufacturing an ophthalmic in a Grade D area without appropriate microbial controls.

You may also be interested in...



FDA Warnings About GMP Violations Aren’t The First For Three US OTC Drug Manufacturers

Ultra Seal, Generitech, and Yusef Manufacturing indicated in responses to FDA inspectors’ findings they weren’t aware of, or capable for complying with some of the requirements imposed on them under FDA regulations for ingredient and product testing and other components of quality control.

The Quality Lowdown: Pandemic Site Evaluation Creativity On Display As COVID Clampdown Returns

With a virtual visit to SciVac in Israel, a belated Revance site inspection in California and two weeks at a Dr. Reddy’s site in India, the US FDA finds ways to overcome travel restrictions in its efforts to oversee drug manufacturing quality.

How Post-Approval GMP Challenges Cooled Novo Nordisk’s Blazing Wegovy Launch

Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS152139

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel